Pre-Conference Tutorial - Monday, April 23, 2007
Alliance Metrics in Bio-Pharma Alliances: Different Tools and Approaches
to Setting Alliance Goals and Measuring Alliance Performance |
Day One: Monday, April 23
Pre-Conference Tutorial
Alliance Metrics in Bio-Pharma Alliances:
Different Tools and Approaches to Setting Alliance Goals and Measuring Alliance Performance
7:00am Pre-Conference Tutorial Registration and Morning Coffee
Join industry peers and experts as they explore how alliance management and business performance can be measured and managed at both the macro and micro levels. Having an understanding of and knowing how to apply performance metrics tools at each stage allows organizations and alliance/project teams to anticipate challenges and increase flexibility and adaptability. Different tools, approaches, and best practices will be shared.
8:00-11:30 Tutorial
Alliance Metrics in Bio-Pharma Alliances
|
|
|
Antoine Alarcon, Director, Alliance Management, sanofi pasteur
|
|
|
Kimberly
Brue, Director, Alliance Management, sanofi pasteur
|
|
|
Stuart Kliman, Head, Pharmaceuticals
Practice Area, Vantage Partners
|
|
|
Michel
Oulerich, Director, Corporate Development, sanofi pasteur
|
|
|
|
Main Conference
11:30am Main Conference Registration
12:30 Chairperson’s Opening Remarks
| 12:45 Building Alliance Management Capability
|
 |
| For the last 15 months or so, Abbott’s Pharma Products Division has been on a
journey to build up our alliance management function. In doing so, we have taken a hard look at our existing capabilities, identified gaps, and moved expeditiously to address them. While both our needs and our capabilities will continue to evolve over time, today we are proud to have in place a strong team, a powerful set of tools, and a senior team aligned around the value of being a great partner. In this presentation, we will review in particular how we have used tools to help provide more transparency, improve coordination internally and with partners, and present a more complete picture of our portfolio of relationships to senior management.
|
|
|
Richard Marshak, General Manager, Alliance Management, Pharmaceutical Products Division, Abbott
|
|
1:30 Merck's Effort to Spread the Word
|
|
As we all know, one of the biggest challenges for Alliance Management in large
organizations is to ensure that the rest of the organization understands the alliance
strategy, is on board with its partnering processes, and has at least a good, behavioral sense of the individual skills and attitudes necessary to work in a partnered environment. In this session you will hear about one of Merck's efforts - the Merck Partnering Summit.
- What is the purpose of the Summit and what challenges is it designed to address?
- What are the specific modules and their intended objectives?
- How does the Summit fit into broader partnering activities?
|
|
Photo
N/A |
Joan A. Lasota, PhD, Senior Director, Alliance Management, Merck & Co., Inc.
|
|
Photo
N/A |
Ellen F. Locker, Executive Director, Alliance Management, Merck & Co., Inc.
|
|
2:15
|
|
One-on-One Meetings and Networking Refreshment Break
|
|
3:00 Structuring Alliance Management to Complement Project Management Practices
|
|
The buzz around alliance management in the biopharmaceutical world has certainly increased over the last few years, and for good reason. As the traditional, fully integrated R&D model has evolved to rely more heavily on external collaborations, companies big and small find themselves needing to manage multiple, complex relationships effectively. The exact form and function of “alliance management”, however, varies from one company to another based on strengths, weaknesses, constraints, corporate cultures, and the very nature of collaborations undertaken. Additionally, given the inherent synergies with project management, existing practices for managing the project environment can strongly influence the design of a separate alliance management function. Furthermore, once a company has determined what model and “best practices” to adopt, effecting the organizational change required to instill new mindsets and skills can be daunting. This presentation will guide participants through practical insights into how to define and implement an alliance management capability that complements project management capabilities and best suits their company’s objectives and requirements by:
- Identifying organizational needs
- Translating needs into an appropriate alliance management framework
- Integrating the new framework into the existing organizational structure
- Defining an implementation plan
- Leading the organization through the change process
- Illustrating how TAP Pharmaceuticals has navigated this process through a comprehensive case study
|
|
|
Jenny Rohde, Director, Alliance Management – TAP Pharmaceuticals
|
|
|
Tim Noffke, PMP, Vice President, Life Sciences – Integrated Project Management Co., Inc.
|
|
3:45 Maintaining a Successful Partnership of a Drug Company and Device Company
|
|
In the early 1990’s Wyeth and Medtronic Sofamor Danek entered into a collaboration capitalizing on the expertise of each company. Wyeth researchers identified and isolated rhBMP-2, recombinant human bone morphogenic protein-2, and Medtronic Sofamor Danek had demonstrated expertise in the development, manufacturing and marketing of spinal implant devices used in the treatment of spinal degenerative diseases and deformities. In 2002, INFUSE Bone Graft was launched in the United States representing a formulation of rhBMP-2 combined with a bovine-derived absorbable collagen sponge for spinal fusion procedures. This original application has led to expanded indications and dosage forms.
- Brief introduction to the Wyeth-Medtronic relationship
- Challenges associated with a partnership of a drug company and a device company
- Examples of processes used to build and maintain the alliance
- How the partnership has expanded
|
 |
Kendra B. Eager, PhD, Assistant Vice President, Alliance Management, Wyeth Pharmaceuticals
|
| |
 |
Steven M. Foster, Vice President and General Manager, Biologics, Medtronic Sofamor Danek
|
| 4:30
|
|
Networking Coffee Break and One-to-One Meetings
|
4:45 Interactive Roundtable Discussions & Report
Outs
Each roundtable will be limited to ten participants. Topics that are more popular will have multiple tables.
Overall Roundtable Discussion
Facilitator: Stuart Kliman, J.D., Head, Pharmaceuticals Practice Area, Vantage Partners
Roundtable Topics include:
1. Alliance Management Strategic Agenda for the Future
Facilitator: Mark Barbato, Vice President Alliance Mgmt, Eli Lilly and Company
2. Managing and Structuring Resources as the Quantity of Alliances Increase
3.
Alliance Governance
Facilitator: Mauri Okamoto-Kearney, VP Product Development & New Product Planning, KAI Pharmaceuticals
Inc.
4.
Appropriating Value in Alliance Management
Facilitator: Antoine Alarcon, Director of Alliance Management, Corp. Dev., Sanofi Pasteur
5. Biopharma Industry and Academic
Collaborations
Facilitator: Srinivasa Rangan, Professor of Strategy and International Business, Babson College
| 6:00
Networking Cocktail Reception and One-to-One Meetings |
|
Maximize Your Experience Onsite at the Alliance Management Congress with One-to-One Meetings!
|
| CHI’s Intro-Net offers you the opportunity to set up meetings throughout the two days with
selected attendees before, during and after this conference, allowing you to connect to the
key people that you want to meet. This online system was designed with your privacy in
mind and is only available to registered session attendees of this event.
|
|
7:15 Close of Day One
|
